Compound tracker
RE104 / luvesilocin.
A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
3 trial rows 1 update rows Latest checked: May 17, 2026 All trials Claim boundary
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Related update rows are shown only when they include visible Last checked text and an explicit Claim boundary.
Backlinks
This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.
Completed / Not yet recruiting / Recruiting
Statuses seen
Trial rows
NCT07489651 Phase 2 Not yet recruiting updated May 15, 2026
- Condition
- Generalized Anxiety Disorder
- Sponsor / institution
- Reunion Neuroscience Inc
- Start date
- Apr 1, 2026
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; not-yet-recruiting Phase 2 status is investigational pipeline evidence, not approval, access, label, reimbursement, or efficacy/safety proof. Registry first/last posted 2026-03-24: randomized triple-masked placebo-controlled Phase 2; estimated n=64; single subcutaneous RE104 30mg vs placebo; primary endpoint HAM-A total-score change at Week 4; estimated completion 2027-04.
NCT07002034 Phase 2 Recruiting updated May 15, 2026
- Condition
- Adjustment Disorder in patients with cancer and other medical illnesses
- Sponsor / institution
- Reunion Neuroscience Inc
- Start date
- Jul 30, 2025
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry watch only; recruiting Phase 2 status is investigational pipeline evidence, not approval, access, label, reimbursement, or efficacy/safety proof. Registry last update posted 2026-05-06: randomized triple-masked parallel dose-controlled Phase 2; estimated n=100; single subcutaneous RE104 30mg vs 1.5mg; primary endpoint MADRS total-score change Day 7; estimated completion 2026-12.
NCT06342310 Phase 2 Completed updated May 15, 2026
- Condition
- Postpartum Depression
- Sponsor / institution
- Reunion Neuroscience Inc
- Start date
- Jun 14, 2024
Tracker note / source boundary
Last checked 2026-05-15 UTC. Claim boundary: ClinicalTrials.gov registry and company-presentation schedule watch only; completed Phase 2 status and company-reported presentation plans do not establish approval, label, reimbursement, access, independent efficacy/safety confirmation, or Phase 3 success. Registry last update posted 2026-05-14: completed multicenter randomized triple-masked parallel dose-controlled Phase 2 in postpartum depression; actual n=84; single subcutaneous RE104 30mg vs 1.5mg; primary endpoint MADRS total-score change Day 7.
Related updates
May 17, 2026 Last checked 2026-05-17 07:00 UTC Trial Update Company
Claim boundary.company schedule/pipeline watch only; no approval/access/final efficacy/safety upgrade.
Last checked: 2026-05-17 07:00 UTC. Reunion May 11 release still verifies RE104/luvesilocin RECONNECT presentation schedule only: APA poster May 18 and ASCP oral May 26. Actual APA/ASCP artifacts/data materials were not verified in this pass. Claim boundary: company schedule/pipeline watch only; no approval/access/final efficacy/safety upgrade.
Source/tracker note
Reunion release excerpt: ASCP Pharmaceutical Pipeline Session May 26, 2026 2:00-2:10 PM ET; APA poster titled RE104: A Novel Psychedelic Agent for Postpartum Depression. Actual meeting materials pending.
Conditions touched
Adjustment Disorder in patients with cancer and other medical illnessesGeneralized Anxiety DisorderPostpartum Depression